Dickmeyer Boyce Financial Management Inc. Makes New Investment in CVS Health Corporation $CVS

Posted by Stanley Muller on Jul 24th, 2026

Dickmeyer Boyce Financial Management Inc. acquired a new stake in CVS Health Corporation (NYSE:CVS – Free Report) in the first quarter, Holdings Channel.com reports. The fund acquired 5,172 shares of the pharmacy operator’s stock, valued at approximately $371,000.

Other hedge funds have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its position in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares in the last quarter. Swiss RE Ltd. purchased a new position in shares of CVS Health in the fourth quarter valued at approximately $26,000. Sankala Group LLC acquired a new position in shares of CVS Health in the fourth quarter valued at approximately $28,000. Global Trust Asset Management LLC increased its stake in CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. acquired a new stake in CVS Health during the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: Analysts and market commentary pointed to improving execution, stronger payer margins, and a modest lift in CVS’s fair value estimate, suggesting Wall Street sees more upside in the stock. CVS Health (CVS) Stock Sees Modest Fair Value Lift As Analysts Raise Targets
Positive Sentiment: Options activity was unusually strong, with traders buying far more call options than normal, which can signal expectations for continued upside.
Positive Sentiment: CVS’s new nationwide pet-prescription service has generated widespread coverage and could support pharmacy traffic and customer engagement. CVS is making it easier for pet owners with a new perk
Neutral Sentiment: Brokerage coverage remains constructive, with CVS receiving a consensus “Moderate Buy” rating and another recent upgrade to Buy, reinforcing a generally favorable analyst stance. CVS Health Corporation (NYSE:CVS) Receives Consensus Rating of “Moderate Buy” from Brokerages
Neutral Sentiment: Several articles highlighted CVS’s community-health investments in Massachusetts, but these are more reputational than immediately material to earnings. CVS Health Helping to Strengthen Communities Across Massachusetts
Negative Sentiment: Henry Ford Health filed a lawsuit against CVS alleging a 340B pricing scheme, which could create legal and reputational risk if the claims gain traction. Henry Ford Health sues CVS, alleges 340B pricing scheme

CVS Health Price Performance

Shares of NYSE:CVS opened at $106.86 on Friday. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $110.68. The firm has a market capitalization of $136.35 billion, a P/E ratio of 47.08, a P/E/G ratio of 1.06 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The company’s fifty day moving average price is $99.98 and its 200 day moving average price is $85.97.

CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter last year, the company posted $2.25 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be paid a $0.665 dividend. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.5%. CVS Health’s payout ratio is currently 117.18%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CVS shares. Weiss Ratings upgraded shares of CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday. Cantor Fitzgerald increased their price objective on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Argus boosted their target price on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Deutsche Bank Aktiengesellschaft upped their price target on CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, UBS Group increased their price target on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Twenty-one investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.38.

View Our Latest Research Report on CVS Health

Insider Activity at CVS Health

In other news, Director Larry Robbins sold 370,462 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 over the last three months. Corporate insiders own 0.85% of the company’s stock.

About CVS Health

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.